Are cancer therapies too targeted?; Teleflex snags FDA clearance for bone delivery tech; Ironwood enters PhII;

> Could cancer therapies be too targeted? Researchers at the Wellcome Trust Sanger Institute have found that narrowly targeted genetic therapies could lead treatments to fail. More

> Teleflex won FDA clearance for its vascular technology designed to deliver drugs to the inner bone. Story

> Ironwood Pharmaceuticals ($IRWD) began a Phase IIa clinical trial of its gastroesophageal reflux disease treatment using Depomed's ($DEPO) Acuform delivery technology. Release

> Researchers at the National Autonomous University of Mexico have developed a nanoparticle that targets cervical cancer cells with minimal side effects. More

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.